SOURCE: GlobeImmune, Inc.

GlobeImmune, Inc.

March 17, 2010 16:12 ET

GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting

Sustained Virologic Response, Pharmacogenomic and Biopsy Analysis of HCV Patients Receiving GI-5005 Therapeutic Vaccine to Be Presented at the Annual Meeting of the European Association for the Study of the Liver

LOUISVILLE, CO--(Marketwire - March 17, 2010) -  GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Vienna, Austria, April 14-18, 2010.

The data to be presented are from the GI-5005-02 trial in patients with chronic HCV infection comparing treatment with GI-5005 plus peginterferon alpha-2a/ribavirin versus peginterferon alfa-2a/ribavirin alone and include sustained virologic response (SVR) rates for subjects who have not been previously treated with an interferon based regimen. Alanine amino transferase (ALT) normalization, biopsy results and pharmacogenomic analyses of the patients will also be presented.

The three abstracts accepted for presentation are:

"GI-5005 Therapeutic Vaccine Plus Peg-IFN/Ribavirin Significantly Improves Virologic Response and ALT Normalization at End-of-Treatment and Improves SVR24 Compared to PEG-IFN/Ribavirin in Genotype-1 Chronic HCV Patients" will be presented by Ira M. Jacobson, M.D., the Vincent Astor distinguished professor of medicine at Weill Cornell Medical College.

"Pharmacogenomic Analysis Reveals Improved Virologic Response in All IL-28B Genotypes in Naïve Genotype 1 Chronic HCV Patients Treated with GI-5005 Therapeutic Vaccine plus Peg-IFN/Ribavirin" will be presented by John G. McHutchison, M.D., associate director of the Duke Clinical Research Institute at Duke University Medical Center.

"GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves Biopsy Necro-Inflammatory Scores and ALT Normalization at 48 Weeks Versus PEG-IFN/Ribavirin In Genontype 1 Chronic HCV Patients" will also be presented by Dr. McHutchison.

The abstracts for the presentations can be viewed online at the EASL Web site: www.easl.eu

GlobeImmune's GI-5005 Tarmogen is a therapeutic vaccine product candidate that contains conserved HCV proteins and is designed to generate an HCV specific T-cell response. Tarmogens are whole, heat-killed recombinant S. cerevisiae yeast that express antigens from one or more disease-related proteins.

About GlobeImmune

GlobeImmune Inc. is a private company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that locate and eliminate cancer cells and/or virally-infected cells. The Company's lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company's lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company's Web site at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.